
News|Articles|May 1, 2002
Health systems/plans share common coverage vision for Clarinex, OTC Claritin
Last month the FDA's Nonprescription Drugs Advisory Committee unanimously supported loratadine's (Claritin, Schering-Plough) switch from prescription to over-the-counter status for treatment of chronic idiopathic urticaria, moving the drug one step closer to full OTC status (see significant event timeline in sidebar).
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Tackling Health Inequities Through Collaboration and Community-Based Care
2
Optimal Physical Activity for Preventing Digestive System Cancers
3
Celiac Disease and Thyroid Disease in Adolescence Linked to the Development of Type 1 Diabetes in Adulthood
4
Fulton County Leaders Discuss Closing Health Gaps and Strengthening Behavioral Health Systems
5
















































